PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Metastatic Solid Tumors
Advanced Solid Tumors

Interventions: Drug: PF-06939999 dose escalation
Drug: PF-06939999 monotherapy
Drug: PF-06939999 in combination with docetaxel

First Posted Date: 2019-02-26

Last Posted Date: 2025-01-13

Lead Sponsor: Pfizer

Target Recruit Count: 54

Registration Number: NCT03854227

Locations: 🇺🇸
Scottsdale Healthcare Hospitals d/b/a HonorHealth, Scottsdale, Arizona, United States
🇺🇸
Virginia G. Piper Cancer Pharmacy, Scottsdale, Arizona, United States
🇺🇸
University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center, Miami, Florida, United States

and more 19 locations

Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: Vehicle (Placebo)
Drug: PF-06700841

First Posted Date: 2019-02-21

Last Posted Date: 2022-06-29

Lead Sponsor: Pfizer

Target Recruit Count: 344

Registration Number: NCT03850483

Locations: 🇯🇵
Tanpopo Skin Clinic, Ota Ku, Tokyo, Japan
🇱🇻
Aesthetic dermatology clinic of Prof. J. Kisis, Riga, Latvia
🇱🇻
Health and Aesthetics Ltd, Riga, Latvia

and more 74 locations

A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: PF-06700841 30 mg
Drug: PF-06700841 45 mg
Drug: Placebo
Drug: PF-06700841 15 mg

First Posted Date: 2019-02-19

Last Posted Date: 2023-11-01

Lead Sponsor: Pfizer

Target Recruit Count: 350

Registration Number: NCT03845517

Locations: 🇺🇸
Stamford Therapeutics Consortium, Stamford, Connecticut, United States
🇺🇸
Institute of Arthritis Research, Idaho Falls, Idaho, United States
🇺🇸
Northshore University Hospital, Manhasset, New York, United States

and more 154 locations

Safety and Efficacy of Lorbrena

Recruiting

Conditions: Non-small Cell Lung Cancer

First Posted Date: 2019-02-18

Last Posted Date: 2025-01-31

Lead Sponsor: Pfizer

Target Recruit Count: 683

Registration Number: NCT03844464

Locations: 🇯🇵
3-22-7, Yoyogi, Shibuya-ku, Tokyo, Japan

Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology

Completed

Conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Interventions: Diagnostic Test: Diagnosis of TTR amyloidosis cardiomyopathy

First Posted Date: 2019-02-15

Last Posted Date: 2024-02-12

Lead Sponsor: Pfizer

Target Recruit Count: 812

Registration Number: NCT03842163

Locations: 🇵🇹
Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal
🇸🇮
University Medical Centre Ljubljana - Department of Cardiology, Ljubljana, Slovenia
🇫🇷
CHU de Nantes, Nantes cedex 1, France

and more 15 locations

Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

Phase 3

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: PPSV23
Biological: 20vPnC
Biological: 13vPnC

First Posted Date: 2019-02-11

Last Posted Date: 2021-02-21

Lead Sponsor: Pfizer

Target Recruit Count: 875

Registration Number: NCT03835975

Locations: 🇺🇸
East Valley Gastroenterology and Hepatology Associates, Chandler, Arizona, United States
🇺🇸
The Pain Center of Arizona, Phoenix, Arizona, United States
🇺🇸
Meridian Clinical Research, LLC, Norfolk, Nebraska, United States

and more 34 locations

Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD

Phase 3

Completed

Conditions: Growth Hormone Deficiency

Interventions: Drug: Genotropin
Drug: somatrogon

First Posted Date: 2019-02-06

Last Posted Date: 2021-10-14

Lead Sponsor: Pfizer

Target Recruit Count: 87

Registration Number: NCT03831880

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇸🇰
Národný ústav detských chorôb, Detská klinika, Bratislava, Slovakia
🇺🇸
Shriners Hospitals for Children, Tampa, Florida, United States

and more 29 locations

Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

Phase 3

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: 13vPnC
Biological: 20vPnC

First Posted Date: 2019-02-04

Last Posted Date: 2020-11-23

Lead Sponsor: Pfizer

Target Recruit Count: 1710

Registration Number: NCT03828617

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Accel Research Sites - Clinical Research Unit, DeLand, Florida, United States
🇺🇸
Meridian Clinical Research, LLC, Dakota Dunes, South Dakota, United States

and more 16 locations

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06650833 alone
Drug: PF-06651600 alone
Drug: PF-06650833 together with PF-06651600

First Posted Date: 2019-02-01

Last Posted Date: 2020-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT03827668

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Diflucan Bioequivalence Study For Transferring The Manufacture

Phase 1

Completed

Conditions: Bioequivalence

Interventions: Drug: Reference drug
Drug: Test drug

First Posted Date: 2019-01-29

Last Posted Date: 2021-07-16

Lead Sponsor: Pfizer

Target Recruit Count: 28

Registration Number: NCT03821480

Locations: 🇰🇷
Chungnam National University Hospital, Clinical Trials Center, Daejeon, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy